Lanean...
Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
AIM: To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS: This study was a prospective, multicenter, one-arm, open-label, phase II trial. Patients with unresectable PC, who showed disease...
Gorde:
| Argitaratua izan da: | World J Gastrointest Oncol |
|---|---|
| Egile Nagusiak: | , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Baishideng Publishing Group Inc
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6304301/ https://ncbi.nlm.nih.gov/pubmed/30595804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4251/wjgo.v10.i12.505 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|